Enquest (ENQ) Gets a Buy from Canaccord Genuity
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Sharp is a 5-star analyst with an average return of 24.5% and a 53.21% success rate. Sharp covers the Energy sector, focusing on stocks such as Arrow Exploration Corp, Vaalco Energy, and Nostrum Oil & Gas.
Enquest has an analyst consensus of Moderate Buy, with a price target consensus of p16.00.
Based on Enquest's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p594.69 million and a net profit of p63.43 million. In comparison, last year the company earned a revenue of p717.06 million and had a GAAP net loss of p9.62 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)
Apogee Therapeutics, Inc. (NASDAQ:APGE) is one of the . On July 7, analyst Edward Nash of Canaccord Genuity reiterated a Buy rating on Apogee Therapeutics, Inc. (NASDAQ:APGE) with a price target of $89. The reiterated bullish sentiment comes after the company released promising results from its APEX study for its drug APG777. The drug is an IL-13 monoclonal antibody aimed at treating atopic dermatitis. The Phase II study met its primary and secondary goals, showing a significant reduction in the Eczema Area and Severity Index score, which is a key measure of disease severity. Notably, improvement was seen as early as Week 2, indicating a strong drug effect. A scientist in a white lab coat working at a bench with biopharmaceutical equipment. Analyst Nash also highlights the ongoing Part B of the APEX study and expects 52-week maintenance data in early 2026. These data are important for confirming the drug's long-term benefits and dosing schedule, which could be quarterly to semi-annual. Apogee Therapeutics, Inc. (NASDAQ:APGE) is a clinical-stage biotech company developing novel biologic drugs for inflammatory and immunology diseases. While we acknowledge the potential of APGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Insider
10 hours ago
- Business Insider
Hermes International (HESAF) was downgraded to a Hold Rating at Jefferies
Jefferies analyst James Grzinic downgraded Hermes International to a Hold today and set a price target of €2,460.00. The company's shares closed last Friday at $2,863.90. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Grzinic covers the Consumer Cyclical sector, focusing on stocks such as Compagnie Financiere Richemont SA, Hermes International, and Ferrari. According to TipRanks, Grzinic has an average return of 3.9% and a 56.82% success rate on recommended stocks. Hermes International has an analyst consensus of Moderate Buy, with a price target consensus of $3,103.90.
Business Insider
10 hours ago
- Business Insider
UBS Sticks to Its Buy Rating for Gerresheimer (0NTI)
In a report released today, Olivier Calvet from UBS maintained a Buy rating on Gerresheimer, with a price target of €75.00. The company's shares closed last Friday at €49.02. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Calvet covers the Industrials sector, focusing on stocks such as CTS Eventim AG & Co. KGaA, Gerresheimer, and Jenoptik. According to TipRanks, Calvet has an average return of 5.6% and a 51.56% success rate on recommended stocks. In addition to UBS, Gerresheimer also received a Buy from J.P. Morgan's David Adlington in a report issued on July 10. However, on July 11, Deutsche Bank maintained a Hold rating on Gerresheimer (LSE: 0NTI).
